

1 **TITLE:** PRESCRIBING PRACTICES AND CLINICAL IMPACT OF NEXT GENERATION
2 SEQUENCING IN ROUTINE PRACTICE IN SOLID TUMORS – REAL WORLD
3 EXPERIENCE IN LMIC

4 **SHORT TITLE:**

5 PRESCRIBING PRACTICES AND CLINICAL IMPACT OF NGS IN SOLID TUMORS:
6 REAL-WORLD LMIC EXPERIENCE

7
8 **AUTHOR'S NAME:**

9
10 ADEEBA ZAKI¹

11 NIDA E ZEHRA¹

12 AQSA SOHAIL¹

13 ZEESHAN ANSAR¹

14 MUNIRA MOOSAJEE¹

15
16 ¹DEPARTMENT OF ONCOLOGY, THE AGA KHAN UNIVERSITY HOSPITAL,
17 KARACHI, PAKISTAN

18
19 **CORRESPONDING AUTHOR:**

20 EMAIL: adeeba.zaki@aku.edu

21
22
23 **AUTHORS CONTRIBUTION:**

24 ALL AUTHORS CONTRIBUTED EQUALLY TO THIS WORK

25 **Abstract**

26 Molecular characterization of disease is essential for precision medicine due to novel predictive
27 biomarkers. Multiple next-generation sequencing (NGS) platforms are available, but their
28 expense and clinical utility vary. Even if a targetable mutation is detected, corresponding drugs
29 may not be available or affordable. No prior studies in Pakistan have focused on integrating NGS
30 results into patient care to assist with therapeutic decision-making and survival outcomes.

31 This retrospective study aimed to evaluate the molecular profiling and therapeutic implications
32 of NGS testing across solid tumors. It included all patients with histologically proven
33 malignancy (metastatic or non-metastatic) who had NGS analysis at Aga Khan University
34 Hospital (AKUH) from June 1, 2020, to June 1, 2023. Foundation One was the NGS platform
35 used. From 2020 to 2023, 192 patients underwent NGS. The majority were male (55.2%) and
36 aged over 50 years (71.9%). The most common indications for NGS were carcinoma of unknown
37 primary (CUP) and lung cancers, representing 26% and 25% respectively, followed by colon
38 (9%) and breast cancers (8%). Most patients had metastatic disease (98.4%). Common mutations
39 in lung cancer were EGFR (16.3%) and KRAS G12C (14.3%). In unknown primary, breast, and
40 colon cancers, the most common mutations were BRAF (8%), PIK3CA (18%), and KRAS
41 (42.1%), respectively. Microsatellite instability (MSI) testing was performed in 95% of patients,
42 with 6% being MSI high. Actionable alterations were detected in 31.8% of patients, but only
43 17.2% received genotype-matched treatment, mostly as a first-line treatment for lung cancer. The
44 primary barriers were drug availability and affordability.

45 Our results show that the implementation of NGS analysis supports clinical decision making.
46 However, these results were applicable to a small percentage of patients. For better compliance
47 and applicability, drug availability and cost of treatment needs to be addressed
48 Keywords: Next generation sequencing, lung cancer, mutation, drug.

49 **Introduction**

50 Cancer is a heterogenous disease. Presence of subpopulation of tumour cells with distinct
51 genotype and phenotype leads to divergent biological behavior within a primary tumor and its
52 metastases, or between tumors of the same histopathological subtype [1]. Genetic variations in
53 both the cancer and inherited genomes are informative for hereditary cancer risk, prognosis, and
54 treatment strategies. Given the increasing number of potential targets for cancer therapies, novel
55 applications have been developed that provide information about the tumour genome to guide
56 therapeutic selection. The application of genetic information to assist with the clinical
57 management of patients with cancer is rapidly expanding into routine care [2].

58 There are numerous genetic testing platforms that can guide cancer care from single gene testing
59 by PCR (polymerase chain reaction) or FISH (Fluorescence in situ hybridization) to
60 comprehensive next generation sequencing. Next generation sequencing (NGS) allows rapid
61 simultaneous sequencing of DNA or RNA samples with a higher sensitivity and provides
62 prognostic information on sensitivity or resistance to drugs [3]. Sequencing applications, both
63 genome-wide and targeted, are revealing complex mutational signatures associated with different
64 types of cancers that are now driving both research and therapeutic decisions [4].

65 Studies have evaluated the decision impact of molecular profiling on treatment and their effect
66 on overall survival [5].

67 Studies have evaluated the cost and impact of NGS use at national level on treatment
68 modification and survival [6]. Jones et al. report a statistically significant difference in survival
69 for patients who showed actionable alterations with subsequent targeted therapy in comparison
70 with patients who, despite showing actionable alterations, did not receive targeted therapy and
71 patients who did not show any actionable alterations on NGS testing in gynecological
72 malignancies [7]. In advanced breast cancer clinical application of NGS, real world data revealed
73 that only 4.7% of patients received molecular guided therapy [8].

74 In resource limited countries, routine use of NGS testing is not possible due to cost and
75 availability of testing facility and subsequent drugs. Therefore, we felt that it was essential to
76 evaluate the prescribing practices of NGS in solid malignancies with a focus on the clinical
77 impact of NGS results in patient care to assist with therapeutic decision making. To our
78 knowledge this is the first study evaluating molecular profiling and its therapeutic implication
79 across solid tumors in Pakistan

80 **Material and Methods**

81 **Patients and sample**

82 For this retrospective observational study, all the patients with histologically proven malignancy
83 in whom tumor genomic profiling test ordered from June 2020 till June 2023 were included.

84 There were no limitations for tumor type, treatment line, metastatic vs non- metastatic disease,
85 performance status or organ function. Patients were tested with either Foundation One CDx test,
86 in house targeted hotspot panel (limited gene testing) via PCR or FISH and/ or Microsatellite
87 instability (MSI) testing by PCR. Foundation One CDx, sequences genes from solid tumor tissue
88 sample and reporting the detected alteration (mutation, amplification, deletion, fusion and also
89 tumor mutational burden) along with suggested targeted therapies against each detected
90 alteration.

91 For this retrospective study, the need for individual patient consent was waived by the ethics
92 committee due to the use of de-identified data. All data were anonymized to ensure
93 confidentiality and privacy. As the study involved the analysis of previously collected data, the
94 ethics committee waived the requirement for obtaining new written or verbal consent from
95 participants. When the genomic profiling tests were initially ordered, patients provided informed
96 written consent to have data from their medical records used in research. The study protocol,
97 including the waiver of consent, was reviewed and approved by the ethics committee of The Aga
98 Khan University and considered under exempted study, ensuring that all ethical considerations
99 were addressed.

100 **Statistical Analysis:**

101 Data was analyzed using STATA 16.0. Mean and Standard Deviation or median and intra
102 quartile range (IQR) were calculated for quantitative continuous variables based on the normality
103 of the variables. Frequency and percentages were calculated for categorical variables.

104 Confounders were controlled through stratification; post stratification Chi-square test was
105 applied. Cox proportional hazard regression was used for multivariable analysis to determine the
106 influence of the following variables: matched and nonmatched treatment given before and after
107 NGS analysis, line of treatment at NGS analysis on survival for the total population. A p-value of
108 less than and equal to 0.05 was considered as statistically significant.

109 **Results:**

110 367 patients underwent genomic profiling from June 2020 to June 2023 at the Aga Khan
111 University Hospital. Clinical and demographic characteristics of patients.

112 192 patients underwent genomic (Next generation sequencing) testing via Foundation One CDx
113 panel (FMI). 13 had limited targeted hotspot testing and 162 had MSI testing alone. Majority
114 were male (58.8%) while 41% were female. On age stratification, FMI testing was done mostly
115 in patients who were > 50 years while MSI alone was done in patients between 30-50 years
116 presenting predominantly with non-metastatic malignancy. 22 malignancies were found in which
117 NGS and MSI was advised by treating physician.

118 The most common indication was carcinoma of unknown primary (CUP) and lung cancer
119 representing 26 % and 25% respectively. This was followed by colon cancer (9%), breast cancer
120 (8%).MSI testing was done solely as an only hotspot test in around 44% of patients, mostly those
121 with colon cancer. Inhouse targeted hotspot test was offered in 13 patients, mostly done in
122 patients with colon cancer. Majority of patients had metastatic disease. NGS testing was
123 recommended in first line of treatment after the diagnosis in majority of the patients. Actionable
124 alterations were detected in 31.8% of which only 17.2% patients received genotype-matched
125 treatment. This was most commonly done in first line treatment for lung cancer. Table 1

126

127

128

129 **Table 1: Demographics**

	NGS -FMI (N=192) %	MSI- AKU (N=162) %	NGS -AKU (N=13) %
Age (Yrs.)			
<30	9 (4.7%)	10 (6.2%)	0
30-50	45 (23.4%)	103 (63.6%)	5 (38.5%)
>50	138 (71.9%)	49 (30.2%)	8 (61.5%)
Sex			
Female	86 (44.8%)	60 (37.0%)	5 (38.5%)
Male	106 (55.2%)	102 (63.0%)	8 (61.5%)
Primary malignancy			
Bone cancer	2 (1.0%)	-	
Breast cancer	16 (8.3%)	-	1 (7.7%)
Cervical cancer	3 (1.6%)	-	
Colon cancer	19 (9.9%)	80 (49.4%)	10 (76.9%)
Esophageal cancer	3 (1.6%)	7 (4.3%)	
Gall Bladder cancer	4 (2.1%)	5 (3.1%)	
gastric cancer	1 (0.5%)	12 (7.4%)	
Head and Neck cancer	2 (1.0%)	-	
Kidney Cancer	1 (0.5%)	-	
Lung cancer	49 (25.5%)	-	
Melanoma	1 (0.5%)	-	1 (7.7%)
Ovarian cancer	4 (2.1%)	2 (1.2%)	
Pancreatic cancer	13 (6.8%)	7 (4.3%)	1 (7.7%)
Prostate cancer	4 (2.1%)	5 (3.1%)	
Rectal cancer	4 (2.1%)	36 (22.2%)	
Skin cancer	1 (0.5%)	-	
Soft Tissue sarcoma	5 (2.6%)	-	
Thyroid cancer	3 (1.6%)	-	
Unknown primary	50 (26.0%)	-	
Urothelial cancer	1 (0.5%)	-	
Uterine cancer	6 (3.1%)	7 (4.3%)	
Neuroendocrine Tumor	-	1 (0.6%)	

Stage			
Metastatic	189 (98.4%)	104 (64.2%)	13 (100%)
Non-metastatic	3 (1.6%)	58 (35.8%)	0
Line of treatment (At the time of NGS)			
First	187 (97.4%)	153 (94.4%)	13 (100%)
Second	5 (2.6%)	9 (5.6%)	0
MSI testing	183 (95.3%)		
MSI-H	6 (3.2%)	27 (16.7%)	-
MSS	177 (96.7%)	135 (83.3%)	-
Tumour mutational burden			
<10 Muts/Mb	123 (64.1%)	-	-
>10 Muts/Mb	23 (12.0%)	-	-
0 Muts/Mb	46 (24.0%)	-	-
Actional alteration	61 (31.8%)	-	3 (23.07%)
No Alteration (Wild type)	131 (68.2%)	-	10 (76.9%)
Genotype matched treatment			
N/A	3 (1.6%)	-	
No	156 (81.3%)	113 (69.7%)	12 (92.3)
Yes	33 (17.2%)	49 (30.2%)	1 (7.6%)
Line of treatment (first/second/third or beyond)			
First Line	17 (8.9%)	35 (21.6%)	1 (7.6%)
N/A	157 (81.8%)	-	-
Second line	18 (9.4%)	14 (8.6%)	-

130

131 GENOMIC LANDSCAPE

132 MSI testing

133 MSI testing was done as a part of Foundation one CDx panel and also as a targeted hotspot test

134 via PCR at institute. Most common indication was colon cancer (49%) followed by rectal cancer

135 (22%) and gastric cancer (7%). In colon cancer, 28.7% patients are found to have MSI -H while
136 71.2% are MSS and most commonly performed in stage II colon cancer. In rectal cancer
137 majority of the patients were MSS (92%) and mostly done in metastatic disease. Matched
138 treatment according to instability testing was given in all patients with colon cancer. MSI testing
139 in patients other than colon cancer was done in metastatic presentation. Table 2

140 **Table 2: MSI testing MSI (N=162)**

Primary malignancy	MSI testing No. (%)	MSI-H No. (%)	MSS No. (%)	Matched treatment No. (%)
Colon cancer	80 (49.4%)	23 (28.7%)	57 (71.2%)	46 (93.9%)
Esophageal cancer	7 (4.3%)	1 (14.2%)	6 (85.7%)	2 (4.1%)
Gall Bladder cancer	5 (3.1%)	5 (100%)	0 (0%)	0 (0%)
Gastric cancer	12 (7.4%)	1 (8.3%)	11 (91.6%)	1 (2.0%)
Ovarian cancer	2 (1.2%)	0 (0%)	2 (100%)	0 (0%)
Pancreatic cancer	7 (4.3%)	0 (0%)	7 (100%)	0 (0%)
Prostate cancer	5 (3.1%)	0 (0%)	5 (100%)	0 (0%)
Rectal cancer	36 (22.2%)	1 (2.7%)	35 (97.2%)	0 (0%)
Uterine cancer	7 (4.3%)	1 (14.2%)	6 (85.7%)	0 (0%)
Neuroendocrine tumor	1 (0.6%)	0 (0%)	1 (100%)	0 (0%)


141
142 **Cancer types and molecular targets and implication on treatment.**
143 22 different cancers genomic profiling were studied. Most common were the Lung cancer,
144 carcinoma of unknown primary, breast and colon cancer. Each with different demographic
145 details, genomic alteration (either targetable or non-targetable), line of treatment and matched

146 treatment as per result. Most actionable alteration were detected in lung cancer. Mostly the
147 patients had upfront testing when diagnosed with metastatic disease.

148 49 patients with lung cancer, 50 with carcinoma of unknown primary, 16 with breast cancer, 92
149 patients with colon cancer underwent NGS (Foundation one) testing. In all cancer type mostly
150 patients were male expect those with breast cancer with age greater than 50 years. Most common
151 mutation detected in lung cancer was EGFR Exon 19 deletion (16.3%), KRAS- G12C
152 amplification (14.3%), ERBB amplification (8.2%) followed by EGFR L858R, CDK 4
153 amplification, BRAF. (Graph 1). Common mutation in carcinoma of unknown primary were
154 BRAF/ MYC amplification (8%), CDK-4 amplification (8%) followed by EGFR amplification,
155 NF-1 loss (6%). (Graph 2). In breast cancer, common mutation was PIK3CA amplification,
156 PTEN (18%) followed by BRCA 2 (12.5%) and BRCA 1 (6.3%) (Graph 3). And in colon cancer
157 common mutation detected were KRAS and TP53 (42.1%) followed by TP53 alone (26.3%). All
158 the patients were Microsatellite stable (MSS) with Tumor mutational burden (TMB) < 10
159 mut/Mb. Only 10.5% of the patients were MSI-H in colon cancer. (Graph 4).


160 Actionable mutation was detected in 30%, 16%, 37% and 47% in lung, carcinoma of unknown
161 primary, breast cancer and colon cancer respectively. Genotype matched treatment was received
162 in 30%, 6%, 12.5% and 36% respectively. Most likely limitation for not receiving genotype
163 matched treatment was due to non – availability of drug and non-affordability.

164 Graph 1: Molecular Alteration detected in NGS – Lung cancer




165

166 Graph 2: Molecular Alteration detected in NGS- Carcinoma of Unknown Primary.



167


168 **Graph 3: Molecular Alteration detected in NGS- Breast Cancer**



169

170

171 **Graph 4: Molecular Alteration detected in NGS- Breast Cancer**



172

173 **Other cancer types:**

174 17 other different cancers genomic profiling were studied. No actionable mutation was detected
 175 in majority of cancer. While in other cancers like esophageal cancer (3 patients), Gall bladder
 176 cancer (4 patients), rectal cancer (4 patients), skin cancer (1 patient), thyroid cancer (3 patients)
 177 and uterine cancer (6 patients), in which actionable alteration were detected but no genotype
 178 matched treatment was given mainly due to non- availability of drugs. Table -3

179 **Table 3: Cancer and Alteration**

Cancer and Alteration	%
Pancreatic Cancer	
CDK4- amplification	8%
ERBB2- amplification	15%
KRAS- G12D	46%
MDM2- amplification	8%
NF1- rearrangement	8%
STK11- loss	8%

Cervical Cancer	
MET- amplification/ ARID1A- S11fs*91	33%
PIK3CA	33%
PIK3CA-	33%
Esophageal Cancer	
ARID1A- Y551fs*68	33%
CCND1- amplification	33%
ERBB2- amplification/ MYC- amplification	33%
Gall Bladder Cancer	
(PD-L1)- amplification/ (PD-L2)- amplification/ KRAS- amplification,	25%
EGFR- amplification-equivocal/ NF1- F2156L	25%
ERBB2-amplification-	50%
Ovarian Cancer	
RAD51B- R47*	25%
CBL- C381Y	25%
NF1- L190*/ MYC- amplification-equivocal/ TP53- R280*	25%
Prostate Cancer	
APC- F1954fs*16/ PIK3R1- T576del, rearrangement intron 7/ PTEN- loss	25%
AR- amplification/ CTNNB1- S45P- subclonal/ PTEN- loss/ RET- amplification	25%
MYC- amplification/ TMPRSS2- TMPRSS2-ERG fusion	25%
NF1- rearrangement intron 13	25%
Rectal Cancer	
KRAS- G12C	25%
NRAS- Q61K	25%
RNF43- R221fs*39	25%

Soft tissue sarcoma	
CDK4- amplification/ MDM2- amplification/	60%
EWSR1- EWSR1-ATF1 fusion	20%
PTEN- loss exons 3-9	20%
Thyroid cancer	
BRCA1- S1253fs*10/ AKT2- amplification/ AKT3- amplification-equivocal/ KEAP1- Y300*/ MTAP- loss exons 5-8	33%
NRAS- Q61R	33%
RET- M918T/ NF1- W221*	33%
Uterine cancer	
PIK3CA	50%
FBXW7- R479*/ PIK3CA-	17%
PIK3R1	17%

180

181 **Discussion:**

182 The success in drug interaction associated with genomic alteration have led to implementation of
183 NGS testing with the capability to sequence many genes for specific cancer in a short period of
184 time. In real world medical practice NGS panel testing ordered by oncologist increasingly but
185 still there is still controversy that whether molecular profiling is needed upfront in all the
186 oncological patients, this issue is still unresolved [9]. In 2020 NGS recommendation were
187 published which proposed that NGS testing must be focused on advanced cancer in which several
188 molecular markers are relevant for the initial treatment like colon cancer, lung cancer,
189 melanoma, unknown primary tumors [10]. Our current study have appraised the integration of

190 NGS into clinical perspective of patient care which can help in assessing therapeutic decision
191 making among solid tumors.

192 Carcinoma of unknown primary always remains a unique challenge to the clinician as
193 represented as a heterogenous group of malignancies with distinct disease course and biology.

194 Studies have shown that progress in genomic profiling elaborate further insight into downstream
195 pathways and cellular system which further aid in subclassification into tumor origin that may
196 sometime help as a therapeutic target [11]. retrospective study on CUP revealed that most
197 common actionable alteration identified were PIK3CA, BRCA2, KRAS mutation, ERBB2
198 amplification and high TMB. Median overall survival for those who treated with molecular
199 guided therapy was 23.6 months as compared to historical data using conventional therapy [12].

200 In our study only 16% of patients with carcinoma of unknown primary found to have actionable
201 alteration and of which 6% received molecular based treatment. Common mutations were
202 BRAF/ MYC amplification, CDK-4 amplification, EGFR amplification, NF-1 loss.

203 In lung cancer (specifically stage IV Non-small cell lung cancer (NSCLC), molecular testing
204 upfront before starting treatment has become standard of care. NGS though saves time and is
205 cost- effective when we compared with gene testing done sequentially but in our resource
206 constraint setting, we are obliged to get sequential testing in some patients. Presley et al. reported
207 29% of actionable mutation via NGS testing [13] also report 61% targeted therapy usage [14].
208 Our study revealed 55% of actionable target alteration which is similar to reported but only 30%
209 of patients received genotype matched treatment which is either due to unavailability of drug or

210 non- affordability. Furthermore, our study did not compare survival outcome between patients
211 undergoing NGS testing versus sequential molecular testing.

212 From the discovery of molecular biomarkers KRAS/NRAS in colon cancer with confers
213 resistance to anti EGFR therapy we have moved to different molecular subtype of metastatic
214 colorectal cancer with different treatment options. Therefore, molecular profiling became
215 essential, and the guideline recommends that all the patients with metastatic colorectal cancer
216 must be tested for . Our study also revealed that the most common mutation detected was
217 KRAS/TP53 and 10% MSI-H with is similar to reported in the studies [15].

218 Improved outcomes were shown in cancer particularly lung cancer, clinical trial screening or rare
219 cancer for making therapeutic decision association with NGS testing when it was performed
220 initially. Median PFS was found to be almost a year in cancer patients with a good performance
221 status and those with early in course of metastatic assessment as compared to those with rapidly
222 progressing tumors and with poor performance status.

223 NGS testing impact actually has some limitation that it only focuses on gene alteration but has
224 not taken into account the patient's general health and on the outcomes associated with test and
225 also improvement in survival has not been addressed clearly. Our study although limited in
226 sample size offers an overview of in which cancer subtype NGS is mostly ordered by oncologist.
227 Our observation strengthens the need of NGS in advanced cancer and the need for improving the
228 understanding of genomic drug association.

229 Our results show that the implementation of NGS analysis does support clinical decision
230 making. However, the results are applicable in small percentage of patients. For better
231 compliance and applicability, drug availability and cost of treatment need to be addressed.

232

233

234

235 **References**

- 236 1. Russnes HG, Navin N, Hicks J, Borresen-Dale AL. Insight into the heterogeneity of
237 breast cancer through next-generation sequencing. *J Clin Invest*. 2011 Oct;121(10):3810-
238 8. doi: 10.1172/JCI57088. Epub 2011 Oct 3. PMID: 21965338; PMCID: PMC3195464.
- 239 2. US Food and Drug Administration. Table of pharmacogenetic associations. Silver Spring,
240 MD: US Food and Drug Administration; 2020.
- 241 3. Malapelle U, Vigliar E, Sgariglia R, Bellevicine C, Colarossi L, Vitale D, Pallante P,
242 Troncone G. Ion Torrent next-generation sequencing for routine identification of
243 clinically relevant mutations in colorectal cancer patients. *J Clin Pathol*. 2015
244 Jan;68(1):64-8. doi: 10.1136/jclinpath-2014-202691. Epub 2014 Nov 5. PMID:
245 25378536.
- 246 4. Levy SE, Boone BE. Next-Generation Sequencing Strategies. *Cold Spring Harb Perspect*
247 *Med*. 2019 Jul 1;9(7):a025791. doi: 10.1101/cshperspect.a025791. PMID: 30323017;
248 PMCID: PMC6601457.

- 249 5. Holt S, Bertelli G, Humphreys I, Valentine W, Durrani S, Pudney D, Rolles M, Moe M,
250 Khawaja S, Sharaiha Y, Brinkworth E, Whelan S, Jones S, Bennett H, Phillips CJ. A
251 decision impact, decision conflict and economic assessment of routine Oncotype DX
252 testing of 146 women with node-negative or pN1mi, ER-positive breast cancer in the
253 U.K. *Br J Cancer*. 2013 Jun 11;108(11):2250-8. doi: 10.1038/bjc.2013.207. Epub 2013
254 May 21. PMID: 23695023; PMCID: PMC3681004.
- 255 6. Coquerelle S, Darlington M, Michel M, Durand M, Borget I, Baffert S, Marino P, Perrier
256 L, Durand-Zaleski I; NGSEco Group. Impact of Next Generation Sequencing on Clinical
257 Practice in Oncology in France: Better Genetic Profiles for Patients Improve Access to
258 Experimental Treatments. *Value Health*. 2020 Jul;23(7):898-906. doi:
259 10.1016/j.jval.2020.03.005. Epub 2020 Jul 18. PMID: 32762992.
- 260 7. Jones TE, Zou J, Tseng GC, Roy S, Bhargava R. The Utility of Next-Generation
261 Sequencing in Advanced Breast and Gynecologic Cancers. *Am J Clin Pathol*. 2021 Aug
262 4;156(3):455-460. doi: 10.1093/ajcp/aqaa256. PMID: 33728425.
- 263 8. Suh KJ, Kim SH, Kim YJ, Shin H, Kang E, Kim EK, Lee S, Woo JW, Na HY, Ahn S,
264 Jang BS, Kim IA, Park SY, Kim JH. Clinical Application of Next-Generation Sequencing
265 in Patients With Breast Cancer: Real-World Data. *J Breast Cancer*. 2022 Oct;25(5):366-
266 378. doi: 10.4048/jbc.2022.25.e30. Epub 2022 Jun 28. PMID: 35914747; PMCID:
267 PMC9629971.
- 268 9. Dienstmann R, Lonardi S. Is upfront full molecular profiling needed in all patients with
269 colorectal cancer in daily practice? *Lancet Oncol*. 2022 Sep;23(9):1129-1131. doi:
270 10.1016/S1470-2045(22)00035-3. PMID: 36055302.

- 271 10. Colomer R, Mondejar R, Romero-Laorden N, Alfranca A, Sanchez-Madrid F, Quintela-
272 Fandino M. When should we order a next generation sequencing test in a patient with
273 cancer? *EClinicalMedicine*. 2020 Jul 31;25:100487. doi: 10.1016/j.eclinm.2020.100487.
274 PMID: 32775973; PMCID: PMC7397394.
- 275 11. Oien KA. Pathologic evaluation of unknown primary cancer. *Semin Oncol*. 2009
276 Feb;36(1):8-37. doi: 10.1053/j.seminoncol.2008.10.009. PMID: 19179185.
- 277 12. Fusco MJ, Knepper TC, Balliu J, Del Cueto A, Laborde JM, Hooda SM, Brohl AS, Bui
278 MM, Hicks JK. Evaluation of Targeted Next-Generation Sequencing for the Management
279 of Patients Diagnosed with a Cancer of Unknown Primary. *Oncologist*. 2022 Feb
280 3;27(1):e9-e17. doi: 10.1093/oncolo/oyab014. PMID: 35305098; PMCID: PMC8842368.
- 281 13. Presley CJ, Tang D, Soulos PR, Chiang AC, Longtine JA, Adelson KB, Herbst RS, Zhu
282 W, Nussbaum NC, Sorg RA, Agarwala V, Abernethy AP, Gross CP. Association of
283 Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-
284 Small Cell Lung Cancer in the Community Oncology Setting. *JAMA*. 2018 Aug
285 7;320(5):469-477. doi: 10.1001/jama.2018.9824. PMID: 30088010; PMCID:
286 PMC6142984.
- 287 14. Al-Ahmadi A, Ardeshir-Larijani F, Fu P, Cao S, Lipka MB, Dowlati A, Bruno DS. Next
288 Generation Sequencing of Advanced Non-Small Cell Lung Cancer: Utilization Based on
289 Race and Impact on Survival. *Clin Lung Cancer*. 2021 Jan;22(1):16-22.e1. doi:
290 10.1016/j.clcc.2020.08.004. Epub 2020 Sep 18. PMID: 33397584..
- 291 15. Bayle A, Basile D, Garinet S, Rance B, Laurent-Puig P, Blons H, Taieb J, Perkins G.
292 Next-Generation Sequencing Targeted Panel in Routine Care for Metastatic Colon

293 Cancers. Cancers (Basel). 2021 Nov 17;13(22):5750. doi: 10.3390/cancers13225750.
294 PMID: 34830904; PMCID: PMC8616114.